Moleculin Biotech Inc (MBRX)
4.45
-0.07
(-1.62%)
USD |
NASDAQ |
Apr 19, 16:00
4.45
0.00 (0.00%)
After-Hours: 20:00
Moleculin Biotech Enterprise Value: -13.47M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | -13.47M |
| April 17, 2024 | -14.02M |
| April 16, 2024 | -14.02M |
| April 15, 2024 | -13.62M |
| April 12, 2024 | -13.24M |
| April 11, 2024 | -12.92M |
| April 10, 2024 | -11.97M |
| April 09, 2024 | -11.90M |
| April 08, 2024 | -12.30M |
| April 05, 2024 | -11.97M |
| April 04, 2024 | -11.74M |
| April 03, 2024 | -11.86M |
| April 02, 2024 | -11.41M |
| April 01, 2024 | -10.92M |
| March 28, 2024 | -10.39M |
| March 27, 2024 | -11.21M |
| March 26, 2024 | -13.13M |
| March 25, 2024 | -11.86M |
| March 22, 2024 | -10.84M |
| March 21, 2024 | -8.782M |
| March 20, 2024 | -9.497M |
| March 19, 2024 | -6.048M |
| March 18, 2024 | -5.173M |
| March 15, 2024 | -7.028M |
| March 14, 2024 | -5.654M |
| Date | Value |
|---|---|
| March 13, 2024 | -4.826M |
| March 12, 2024 | -4.802M |
| March 11, 2024 | -2.433M |
| March 08, 2024 | -1.027M |
| March 07, 2024 | -1.164M |
| March 06, 2024 | -1.164M |
| March 05, 2024 | -1.03M |
| March 04, 2024 | -0.5622M |
| March 01, 2024 | -3.135M |
| February 29, 2024 | -2.534M |
| February 28, 2024 | -3.172M |
| February 27, 2024 | -2.968M |
| February 26, 2024 | -3.87M |
| February 23, 2024 | -5.514M |
| February 22, 2024 | -6.343M |
| February 21, 2024 | -6.803M |
| February 20, 2024 | -6.850M |
| February 16, 2024 | -6.927M |
| February 15, 2024 | -6.844M |
| February 14, 2024 | -6.516M |
| February 13, 2024 | -6.510M |
| February 12, 2024 | -6.276M |
| February 09, 2024 | -6.289M |
| February 08, 2024 | -7.078M |
| February 07, 2024 | -6.176M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-35.75M
Minimum
Mar 14 2022
141.14M
Maximum
Feb 10 2021
11.23M
Average
1.924M
Median
Enterprise Value Benchmarks
| Merck & Co Inc | 345.18B |
| Lixte Biotechnology Holdings Inc | 6.834M |
| Moderna Inc | 30.45B |
| NovaBay Pharmaceuticals Inc | 2.485M |
| Palatin Technologies Inc | 21.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.27M |
| Total Expenses (Quarterly) | 8.919M |
| EPS Diluted (Quarterly) | -5.245 |
| Earnings Yield | -343.7% |